0 0
Read Time:1 Minute, 36 Second

BDR Pharmaceutical today announces the launch of 100mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Nintenib is priced at INR 750 (100 mg) and INR 900 (150 mg) for a pack of 10 tabs.

Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis (1). The median survival in IPF patients is 2.5 to 3.5 years. Nintedanib received DCGI approval after showing a significant slowdown in the disease progression in patients with pulmonary fibrosis by reducing the rate of decline in forced vital capacity (FVC) in patients with IPF and mild or moderate lung function impairment.

Currently, there are two clinical trials being conducted to study the safety and efficacy of Nintedanib for the treatment of moderately to critically ill COVID-19 patients suffering from IPF.

Mr. Dharmesh Shah, CMD, BDR Pharmaceuticals said, “We are thrilled to innovate and work towards introducing newer, effective and affordable treatment options for patients. We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for COVID-19 patients. We are happy to lend our hand in any way to ensure the community is better prepared during this pandemic. With the launch of Nintedanib, we are on the verge of changing the therapeutic dynamics in the segment of tyrosine kinase inhibitors”.

Nintedanib is a small molecule tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) involved in signaling pathways which lead to its use in pulmonary fibrosis. It has also shown significant efficacy in the management of non-small cell carcinoma of the lung as well as systemic sclerosis.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleppy
Sleppy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

One thought on “BDR Pharma launches Nintenib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis in India

  1. On September 28, 2016, my partner Allen’s pulmonologist told him to go home and get his affairs in order, because he only had 30 days to live. At that time, his biopsy showed severe idiopathic pulmonary fibrosis (IPF). Allen’s IPF caused him to struggle with many common daily activities. For instance, walking just 10 feet would leave him feeling dizzy and ready to fall. He had to use a walker to get from his living room chair to the bathroom. Even on supplemental oxygen, he had no energy.Allen began doing all the research he could on his condition and treatment options. At first, he was discouraged by the lack of information and support groups for IPF — the support groups he found were for people with COPD. Then, Allen found the multivitamincare.org website, and everything started to change for him.After his treatment, he doesn’t need his walker to get around anymore, and he’s been able to walk short distances and exercise his legs. He still needs supplemental oxygen, but the amount he uses hasn’t increased. He’s been able to go on an Alaskan cruise with his friends without feeling like a burden. He’s also been able to travel to beaches along the Oregon coast and watch whales in the bay. He says he likes being able to go places, get out of the car and take in the sights. Before multivitamin herbal formula, he wouldn’t have been able to travel or sustain the energy for sightseeing.
    Now, Allen says he feels so lucky to be alive after his doctor told him he only had 30 days left. Because of the results from his treatment, Allen has a short, sweet piece of advice for other chronic lung disease patients considering getting help from multivitamin herbal remedy.

Leave a Reply

Your email address will not be published. Required fields are marked *